Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended September 30, 2025. Sonoma Pharmaceuticals, Inc. is a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for wound care, eye care, dermatology, podiatry, animal health, and disinfection. The company operates in 55 countries and is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2025 | Six Months Ended Sept 30, 2025 |
|---|---|---|
| Revenue | $5.60 million | $9.62 million |
| Gross Profit | $2.12 million (38% margin) | $3.58 million (37% margin) |
| Net Loss | $(0.53) million | $(1.78) million |
| Net Loss Per Share (Basic/Diluted) | $(0.32) | $(1.08) |
| Cash and Cash Equivalents | $3.04 million (Sept 30, 2025) | N/A |
| Working Capital | $8.18 million (Sept 30, 2025) | N/A |
| Short-Term Debt | $0.06 million | N/A |
| Accumulated Deficit | $(199.58) million | N/A |
Cash Flow (Six Months Ended Sept 30, 2025): Net cash used in operating activities was $2.65 million. Net cash used in investing activities was $0.12 million. Net cash used in financing activities was $0.12 million.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 57% year-over-year for the quarter ($5.60M vs. $3.58M) and 38% for the six-month period ($9.62M vs. $6.97M). Growth was driven by increased demand in the U.S. (up 115% QoQ) and Europe (up 43% QoQ).
- Profitability: While the company remains unprofitable, the net loss narrowed slightly on a quarterly basis ($0.53M vs. $0.61M prior year) due to revenue growth outpacing expense increases.
- Expense Management: Selling, General, and Administrative (SG&A) expenses increased 10% quarter-over-quarter but decreased as a percentage of revenue from 48% to 34% due to top-line growth.
- Liquidity: Cash balances decreased from $5.37 million at March 31, 2025, to $3.04 million at September 30, 2025, primarily due to operating cash burn.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management explicitly states there is substantial doubt about the company's ability to continue as a going concern within one year due to its history of losses and reliance on future financing. The financial statements do not include adjustments that might be necessary if the company cannot continue operations.
- Capital Needs: The company anticipates needing additional capital through equity offerings, debt, or collaborations. There is no assurance such financing will be available on acceptable terms.
- Operational Updates:
- Launched new dermatology products in the U.S. and expanded distribution agreements (e.g., Medline Industries, WellSpring Pharmaceutical).
- Subsequent events include the sale of 51,436 shares in October 2025 for net proceeds of $170,000.
- Amended CEO employment agreement (Oct 2025) and terminated the Executive Vice President/COO (Oct 2025).
- Risks: Key risks include foreign currency fluctuations (Mexico Peso, Euro), dependence on key customers (Customer C represented 17-19% of revenue), and a substantial Mexico tax liability due in 2027.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $3.04 million cash balance against the $2.65 million operating cash burn rate for the last six months.
- Financing Plans: Confirm the status of any upcoming equity offerings or debt financings required to address the "substantial doubt" going concern warning.
- Customer Concentration: Assess the risk associated with Customer C, which accounted for approximately 18% of revenue in the six-month period.
- Tax Liability: Review the details of the substantial Mexico tax liability and intercompany debt due in 2027 to understand potential future cash outflows.
- Executive Turnover: Evaluate the impact of the recent termination of the Executive Vice President/COO on operational stability.